Bullish Case: IQV has reclaimed $278 with strong momentum (+30.8% YoY, +15.3% in 90 days) and calls out-traded puts 30%. The Veeva partnership expansion (Oct 14) reinforces the clinical-trials data moat, while Helium's density places peak probability right at $270–$290. Mid-curve IV near 37–40% looks rich versus quiet realized trends, so IV compression plus drift could carry shares toward $300–$310 into early 2027.

Bearish Case: At 7.1x book after a 30%+ run, IQV is priced for flawless execution. Helium's own AI signal is -2.95%, and the term structure is backwardated (Nov ~54% IV vs Aug ~37%), signaling near-term event fear despite flat labeling. A 340B/payer-policy shock is live: the Nov 2 HR Dive piece weaponizes IQV's own study showing payers absorbing 68% of the spread, inviting scrutiny that could hit CRO bookings. A miss or guidance cut could retrace quickly toward $250–$260.

Potential Outcomes:

1. In-line consolidation (40%): price $270–$290 through Q1; Nov IV decays from ~54% toward Dec's ~33–43% band. Falsifiable if Nov expiry IV stays >45% after Nov 21.
2. Beat/raise or contract catalyst (20%): +8–14% toward $300–$315; IV compresses 3–5pp. Falsifiable on EPS beat ≥3% plus raised guidance.
3. Miss/guide-down (25%): -10–15% toward $245–$255; short-dated put IV spikes >45%. Falsifiable on EPS miss ≥3%.
4. 340B/policy or client-loss shock (10%): -15%+ on explicit adverse disclosure.
5. M&A/large RFP win (5%): +12%+ discrete re-rate on >$200M announcement.

Sum = 100%. Prior cycles (Feb–Oct) repeatedly over-weighted 'in-line' at 44–45% and under-called beat outcomes; with momentum and call skew now positive, I shift weight toward continuation, though the near-dated 54% IV print is the strongest falsifiable bear signal on the board.

November 10, 2026